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Abstract
Nutrient availability is the major regulator of life and reproduc-
tion, and a complex cellular signaling network has evolved to
adapt organisms to fasting. These sensor pathways monitor cellu-
lar energy metabolism, especially mitochondrial ATP production
and NAD+/NADH ratio, as major signals for nutritional state. We
hypothesized that these signals would be modified by mitochon-
drial respiratory chain disease, because of inefficient NADH utiliza-
tion and ATP production. Oral administration of nicotinamide
riboside (NR), a vitamin B3 and NAD+ precursor, was previously
shown to boost NAD+ levels in mice and to induce mitochondrial
biogenesis. Here, we treated mitochondrial myopathy mice with
NR. This vitamin effectively delayed early- and late-stage disease
progression, by robustly inducing mitochondrial biogenesis in skel-
etal muscle and brown adipose tissue, preventing mitochondrial
ultrastructure abnormalities and mtDNA deletion formation. NR
further stimulated mitochondrial unfolded protein response,
suggesting its protective role in mitochondrial disease. These
results indicate that NR and strategies boosting NAD+ levels are a
promising treatment strategy for mitochondrial myopathy.
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Introduction
Mitochondrial disorders, caused by respiratory chain deficiency
(RCD), are the most common form of inherited metabolic disorders
and manifest with exceptional clinical variability (Ylikallio &
Suomalainen, 2011). Despite their progressive and often fatal
outcome, no curative treatment is available. Therapy trials for these
diseases are mostly hampered by heterogeneity of the disease mani-
festations and the consequent lack of patient groups with homoge-
nous genetic background and clinical presentations (Suomalainen,
2011). Development of mouse models replicating mitochondrial
disease phenotypes has provided a unique opportunity both for
therapeutic trials and for detailed studies of molecular pathophysiol-
ogy of primary mitochondrial dysfunction.
We have previously generated Deletor mice, with adult-onset
mitochondrial myopathy (MM) (Tyynismaa et al, 2005). These mice
carry a dominant patient mutation in mitochondrial replicative heli-
case Twinkle, resulting in progressive MM after 12 months of age,
with the accumulation of multiple mtDNA deletions in their skeletal
muscle and brain, leading to a subtle progressive respiratory chain
deficiency (Zeviani et al, 1989; Suomalainen et al, 1992; Tyynismaa
et al, 2005). These mice have a normal lifespan and physical perfor-
mance despite typical morphological changes in MM, cytochrome c
oxidase (COX)-negative fibers, and ultrastructural mitochondrial
abnormalities, in their muscle. The histological and physiological
findings in Deletors mimic closely those of patients with the same
mutation (Suomalainen et al, 1992, 1997), making Deletor mice an
optimal model for therapy trials.
We found that RCD in Deletor muscles induced a pseudo-
starvation response, despite normal food intake, with wide induc-
tion of genes with the ATF transcription factor-binding sites in their
upstream regulatory regions (Tyynismaa et al, 2010). One of these
genes was FGF21, encoding a fasting cytokine and leading to
increased blood FGF21 concentration and consequent fat mobiliza-
tion from adipose tissue and liver (Kharitonenkov et al, 2005), with-
out, however, activation of fasting-related beta oxidation or
mitochondrial biogenesis. This suggested that RCD induces only
some fasting-related pathways, raising the question whether such
conflicting signaling, partially promoting catabolism, partially anab-
olism, could contribute to disease progression. In C. elegans, ATFs
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have been linked to mitochondrial unfolded protein response
(UPRmt) (Nargund et al, 2012), induced by mitochondrial proteosta-
sis, activating ClpP protease (Haynes et al, 2007, 2013), leading to
ATF relocalization to nucleus and induction of UPRmt-associated
gene expression (e.g., mitochondrial heat shock proteins, HSPs).
The MM-linked pseudo-starvation response with potential links to
UPRmt strongly supported the involvement of abnormal nutrient
signaling in the disease process.
Nutrient sensors Sirt1 and AMPK monitor tissue NAD+/NADH
and AMP/ATP ratios, respectively. If these ratios increased, the
sensors induce a metabolic fasting response, boosting mitochondrial
biogenesis, fatty acid oxidation, and oxidative ATP production (Imai
et al, 2000; Rodgers et al, 2005; Canto et al, 2009, 2012). We
hypothesized that RCD reduces NADH utilization, decreasing
NAD+/NADH and signaling for high nutrient availability, leaving
Sirt1 inactive and attenuating mitochondrial biogenesis. However,
RCD also decreases ATP production, increasing AMP/ATP, signaling
for low nutrition availability, and leading to a potential conflict in
nutrient sensor activation and a partial pseudo-starvation response
(Nunnari & Suomalainen, 2012). Previous treatment trials of
RC-deficient mice have indicated that activation of mitochondrial
biogenesis may be beneficial: High-fat diet (Ahola-Erkkila et al,
2010), PPAR (Wenz et al, 2008; Yatsuga & Suomalainen, 2011) and
AMPK agonists (Viscomi et al, 2011) all delayed disease progres-
sion. Recently, nicotinamide riboside (NR), a vitamin B3-analogue
and NAD+ precursor, was shown to promote oxidative metabolism
in mice by increasing NAD+/NADH (Bieganowski & Brenner, 2004;
Canto et al, 2012). Furthermore, NAD+ precursors improved mito-
chondrial function in aging mice to mimic that of young mice, in
SIRT1-dependent manner (Gomes et al, 2013). We asked here
whether NR could affect the MM pseudo-starvation response and
attenuate the disease progression.
Results
We administered 400 mg/kg/day of NR, or chow diet (CD), for two
groups of male Deletor and control mice (Yang et al, 2007; Canto
et al, 2012): “pre-manifestation” (12 months at initiation, 16 months
at termination), to test whether early NR treatment can prevent MM,
and “post-manifestation” (17 months at initiation, 21 months at
termination), to test whether NR can affect the progression of an
already-manifested disease. The control groups received similar chow
diet without NR. The dose and study protocol were exactly as
published previously (Canto et al, 2012), because they showed that
this dose of NR efficiently increased NAD+ in skeletal muscle.
NR increased mitochondrial biogenesis in skeletal muscle and
ameliorated hallmarks of mitochondrial myopathy
We first analyzed the NAD+ content of Deletor mouse muscle, to
clarify whether respiratory chain deficiency affected this pool. Very
old Deletor mice, from 23 to 27 months of age, showed a decreasing
trend in their skeletal muscle (Fig 1A), whereas younger mice of
17–21 months showed a variation in their NAD+ levels with no
clear decrease (Supplementary Fig S1). These results suggest that
NAD+ pool was progressively depleted upon mitochondrial myopa-
thy progression.
After 16 weeks of NR treatment, the amount of muscle fibers
with decreased cytochrome c oxidase activity (COX-negative),
a hallmark of MM and a measure of disease progression, was
significantly lower in quadriceps femoris muscle (QF) of both pre-
and post-manifestation Deletors compared to the CD-fed Deletors.
The post-manifestation Deletors on NR diet showed 1.8-fold less,
and pre-manifestation mice 1.5-fold less, COX-negative fibers than
Deletors on CD (Fig 1B). The wild-type littermates showed no COX-
negative fibers. The overall histochemical COX activity in both
oxidative and non-oxidative muscle fibers was increased in all mice
receiving NR (Fig 1C), and the amounts of oxidative phosphoryla-
tion enzymes having mtDNA-encoded subunits, especially ATPase,
were increased (Fig 1D–H). Multiple mtDNA deletions in the Deletor
mouse accumulate in the skeletal muscle along with MM progres-
sion and are thought to underlie RCD in both mice and men
(Zeviani et al, 1989; Suomalainen et al, 1992; Tyynismaa et al, 2005).
Consistent with a decrease in COX-negative fibers, both NR-fed
Deletor groups had significantly lower mtDNA deletion load in QF
than CD-fed Deletors (Fig 1I and J), indicating that their accumula-
tion in Deletor tissues was considerably slowed down. NR treatment
increased mtDNA copy number in QF of WT mice, and mtDNA
amount also trended upwards in Deletors (Fig 1K). Citrate synthase
activity indicated an significantly increased mitochondrial mass in
all NR-fed mice (Fig 1L). These results demonstrate that NR induced
mitochondrial biogenesis and oxidative ATP production capacity
robustly and significantly delayed the progression of MM, irrespec-
tive of the disease stage.
NR prevented the development of mitochondrial ultrastructural
abnormalities in mitochondrial myopathy
The electron microscopic examination of skeletal muscle ultrastruc-
ture on CD showed swollen mitochondria increased in number, with
distorted cristae and subsarcolemmal accumulations, accompanied
by myofibrillar degeneration and autophagosomes, especially
evident in oxidative, but also in glycolytic fibers (Fig 2A–C), similar
to previously reported in MM patients (Suomalainen et al, 1992).
On NR diet, the Deletor and WT mice showed a remarkable induc-
tion of mitochondrial biogenesis, with an increase in the amount
and volume of intermyofibrillar and subsarcolemmal mitochondria
(Fig 2D–F and H), with mitochondria-rich pockets around vessels
(Fig 2E), similar to those observed in QF of Deletors on high-fat diet
(Ahola-Erkkila et al, 2010). Importantly, the mitochondrial ultra-
structure of NR-fed Deletors was completely normal, with dense
matrices and crista content similar to WT mice on CD (Fig 2F and
I), indicating active oxidative metabolism. NR increased further the
WT mice matrix and crista density (Fig 2H and I). These findings
suggest that NR treatment induces robust mitochondrial biogenesis
and prevents the development of ultrastructural abnormalities upon
mitochondrial disease.
NR enhanced lipid oxidation in brown adipose tissue and liver
and rescued Deletor BAT phenotype
On NR diet, whole-body O2 consumption and CO2 production of
Deletors showed a significant increase upon cold exposure, reaching
the maximal gas exchange in 4 h, similar to WT mice. Deletors
on CD did not succeed to reach the same level even after 6 h
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(Fig 3A–D, Supplementary Fig S2A–F), suggesting brown adipose
tissue (BAT) dysfunction. Indeed, Deletor BAT showed multiple
mtDNA deletions (Supplementary Fig S4A), low lipid amounts
(Fig 3E–H), and pale mitochondria with low crista content (Fig 3I–L).
NR decreased BAT lipid content and increased mitochondrial
number, size, and matrix density (Fig 3J and L) in both Deletors and
WT mice. BAT of Deletors on NR showed 1.7-fold higher mitochondrial
crista content than that of Deletors on CD, reaching the level of WT
on CD (Fig 3M). Deletor mtDNA amount increased 1.7-fold after NR
(Fig 3N). In WT mice, NR also increased mitochondrial crista
A B C D
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Figure 1. Nicotinamide riboside (NR) induces mitochondrial biogenesis and effectively ameliorates morphological and genetic landmarks of mitochondrial
myopathy.
A Skeletal muscle NAD+ content in 23- to 27-month-old Deletors and WT mice (n = 5 in each group).
B Quantification of muscle fibers showing decreased COX activity in histochemical analysis of frozen sections of quadriceps femoris muscle (total fibers n = 2000
counted per mouse); diet started before disease manifestation (pre-manifestation, “pre”; Deletor NR n = 5; Deletor CD n = 4); diet started after disease manifestation
(post-manifestation, “post”; Deletor NR n = 12; CD n = 11).
C Quantification of the overall histochemical COX activity in muscle. Total intensity of activity in the quadriceps femoris muscle measured (n = 6 in each group).
D Mitochondrial respiratory complex protein and ATPase protein amounts in quadriceps femoris muscle. Western blot analysis of post-manifestation NR- and CD-fed
mouse groups. Representative results shown. CI, respiratory chain complex I, 39-kDa subunit; CII, complex II, 70-kDa subunit; CIV, complex IV, cytochrome c oxidase,
COI subunit, 40 kDa; CV, complex V, ATPase, alpha subunit, 55 kDa. Tubulin indicates the loading control.
E–H Quantification of the respiratory chain complex amounts from Western blots (Fig 1D). (Deletor NR n = 8; Deletor CD n = 8, WT NR n = 6, WT CD n = 6).
I Multiple mtDNA deletions in quadriceps femoris muscle. Long-range PCR amplification. 16.6 kb: amplification product from full-length mtDNA; bracket: smear
representing deleted mtDNA species; 549 bp, product from 12S rRNA gene in mtDNA, not carrying deletions and representing total mtDNA. Representative image
(pre-treatment Deletor NR n = 5; Deletor CD n = 4; post-manifestation Deletor NR n = 12; Deletor CD n = 11).
J Quantification of mtDNA deletion load (H). Pre- and post-manifestation NR- and CD (pre-manifestation; Deletor NR n = 5; Deletor CD n = 4), (post-manifestation;
Deletor NR n = 12; CD n = 11).
K mtDNA copy number in quadriceps femoris muscle. Quantitative PCR analysis, using beta-actin gene as a nuclear two-copy control gene (post-manifestation Deletor
NR n = 12; Deletor CD n = 11, WT NR n = 8, WT CD n = 7).
L Citrate synthase (CS) activity in quadriceps femoris muscle (n = 5 in each group). Numbers above columns indicate P-values. All values are presented as
mean  s.e.m. (Student’s t-test).
NR, nicotinamide riboside; CD, chow diet; Del, Deletor; WT, wild-type mice; pre, pre-manifestation age group; post, post-manifestation age group; COX, cytochrome c
oxidase; CI-CIV respiratory chain complexes I-IV; CV, ATP synthase; AU, arbitrary units.
Source data are available for this figure.
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content and mtDNA amount in BAT (Fig 3K–N). These results indi-
cate that NR induced a robust increase in mitochondrial biogenesis
and mitochondrial function of BAT in both WT and MM mice and
considerably improved the mitochondrial ultrastructure in Deletors.
The Deletor liver showed low lipid content (Ahola-Erkkila et al,
2010; Tyynismaa et al, 2010), which was further decreased by NR,
similar to WT (Supplementary Fig S3A–D). Liver function tests indi-
cated no manifest liver damage on either diet (Supplementary Fig
S3I–J). The mitochondrial ultrastructure was normal in Deletor
hepatocytes (Fig 3P and R), which is consistent with the absence of
mtDNA deletions in the livers of Deletors or patients (Suomalainen
et al, 1992; Tyynismaa et al, 2005). This suggests that liver pheno-
type is secondary to metabolic signals induced by RCD in the skele-
tal muscle and BAT. NR, however, increased mtDNA copy number
in WT (Fig 3O) and changed ultrastructure of rough endoplasmic
reticulum, showing close association of the membranes with mito-
chondria and a suggestive increase in ribosomes on mitochondria in
both Deletor and WT (Fig 3Q and S). These findings suggest the
induction of metabolic activity in the liver. NR did not clearly affect
mtDNA deletion load or copy number in the Deletor brain
A B C
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Figure 2. NR induces skeletal muscle mitochondrial mass and prevents the development of mitochondrial ultrastructural abnormalities in mitochondrial
myopathy.
A–C Deletor quadriceps femoris muscle ultrastructure on chow diet shows increased amount of swollen mitochondria with concentric crista abnormalities (arrows)
especially in subsarcolemmal regions.
D–F Deletors on NR diet. Mitochondria with normal ultrastructure and dense matrices are prominent subsarcolemmally (D–F), especially around the vessels (E, arrows),
and also intramyofibrillar mitochondria show increased volume and matrix density (D, arrows). NR-fed Deletors show high crista density (F).
G WT mice on CD, showing subsarcolemmal mitochondria (arrow).
H WT mouse on NR diet with remarkable accumulation of subsarcolemmal mitochondria with dense matrices, and high crista density.
I Quantification of mitochondrial crista density in Deletors and WT mice on CD or NR diets. In image analysis, a “measuring stick” of 1 lm, placed perpendicular
to the crista lamellae, was used to count crista content. A total of 20 lm of mitochondrial length was calculated per each sample electron micrograph. n = 3 in
each group.
Data information: Numbers above columns indicate P-values. All values are presented as mean  s.e.m. (Student’s t-test). Bars in electron micrographs indicate
magnification. Del, Deletor; WT, wild-type mice; CD, chow diet; NR, nicotinamide riboside; V, blood vessel; E, erythrocyte.
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(Supplementary Fig S4B and C). Whether NR crosses the
blood–brain barrier remains to be confirmed (Canto et al, 2012).
NR enhanced FOXO1 deacetylation, suggesting SIRT1 activation
NR had many beneficial effects on morphological hallmarks of
MM and has previously been shown to boost tissue NAD+ levels
as well as Sirt1 activity, as measured by FOXO1 deacetylation
(Brunet et al, 2004; Canto et al, 2012). The steady-state NAD+
levels showed an increasing trend in mouse livers and muscle after
16 weeks of NR diet, but these steady-state changes after long-term
diet were subtle (Supplementary Fig S1A and B). However, NR
significantly decreased the acetylated inactive form of FOXO1 in
both Deletor and WT mouse muscle and increased the total
amount of FOXO1 in Deletors (Fig 4A–C). These results support
the induction of NAD+-stimulated Sirt1 deacetylase function. Acti-
vation of fatty acid beta oxidation was suggested by increased
mRNA expression levels of long-chain fatty acid transport receptor,
CD36, and two enzymes of fatty acid oxidation pathway, ACOX1
and MCAD (Fig 4D–F). These results suggest that NR was capable
of activating NAD+-responsive sirtuin signaling and downstream
mitochondrial biogenesis.
RCD induced mitochondrial unfolded protein response and is
further enhanced by NR
UPRmt has been suggested to be beneficial for health and lifespan
(Houtkooper et al, 2010; Mouchiroud et al, 2013) and to overlap
with RCD-induced pseudo-starvation response (Tyynismaa et al,
2010; Suomalainen et al, 2011; Nunnari & Suomalainen, 2012). Of
note, we show here that Deletors on CD show the induction of
HSP60, HSP70, and ClpP expression, as well as the AARE-regulated
FGF21 (Fig 4G and H), indicating that RCD induces UPRmt through
mechanisms that are conserved between worms and mammals
(Durieux et al, 2011; Houtkooper et al, 2013). NR further increased
UPRmt protein amounts. These results indicate that UPRmt is
induced by RCD and suggest that NAD+/NADH contributes to
UPRmt induction.
Discussion
Mitochondrial myopathy is one of the most common manifestations
of adult-onset mitochondrial disorders (Ylikallio & Suomalainen,
2011) and is progressive in nature. Currently, only palliative care
can be offered to the patients. We demonstrate here that oral
supplementation with NR, a vitamin B3 form and NAD+ precursor,
efficiently prevented development and progression of mitochondrial
myopathy in mice. NR delayed the development of morphological
hallmarks and ultrastructural changes in mitochondria and resulted
in a remarkable induction of mitochondrial biogenesis and oxida-
tive metabolism, with an increase in mitochondrial mass, mtDNA,
and respiratory chain protein amounts in the muscle. Moreover,
NR-fed Deletors showed less mutant mtDNA than their CD-fed
littermates, which could be a result of decreased generation of
mtDNA deletions or their increased clearance. We show that NR
significantly delayed disease progression even in mice that already
manifested the disease, which is the time, when medical treatment
would typically be started for patients. These results are remark-
able, as they underline the utmost importance of specific vitamin
cofactors as modifiers of metabolism in disease, and emphasize the
role of nutritional signaling in the pathogenesis of adult-onset mito-
chondrial disorders.
Mitochondrial biogenesis induction as a treatment strategy was
first proposed by Moraes group as their chemical or transgenic
induction of PGC1alpha transcription coactivator in severe mito-
chondrial COX deficiency improved RC function and delayed death
of the mice (Wenz et al, 2008). These findings were replicated in
other models of mitochondrial dysfunction (Viscomi et al, 2011;
Yatsuga & Suomalainen, 2011). The link to nutritional signaling
was underlined by the improvement of mitochondrial pathology
after high-fat diet (Ahola-Erkkila et al, 2010) and treatment by
AMPK agonist AICAR (Viscomi et al, 2011) or rapamycin (Johnson
et al, 2013). In wild-type mice, using an identical treatment proto-
col as ours, NR was recently shown to increase tissue NAD+
levels and to induce FOXO1 deacetylation, indicating the activation
of Sirt1 deacetylase (Canto et al, 2012). As Canto et al, we found
in MM mice signs of sirtuin activation after NR treatment. NR
induced FOXO1 deacetylation, which points to Sirt1 activation.
The sirtuin-mediated fasting response has potential to activate the
downstream target PGC1alpha and mitochondrial biogenesis. This
mechanism may underlie the slowed-down disease progression.
These findings propose that similar consequences on mitochondrial
biogenesis, which have been previously obtained by pharmacologi-
cal induction of PGC1alpha, can be achieved by vitamin B3
supplementation.
The role of BAT in mitochondrial disease is a little studied field.
Patients with a specific mtDNA mutation, m.8344A>G, show
multiple symmetric lipomas, which have recently been reported to
contain UCP1-positive adipocytes, typical for BAT (Plummer et al,
2013). This observation suggested that mitochondrial dysfunction
may affect BAT differentiation or function, but the mechanisms
involved are unknown. Cold stimulus activates BAT and results in
increased oxygen consumption. We found that Deletors responded
to cold by increasing their oxygen consumption and CO2 production,
but not to similar level as their wild-type littermates, which
suggested BAT dysfunction. Indeed, the Deletors showed multiple
mtDNA deletions in BAT, and their mitochondrial ultrastructure
showed low crista content and matrix density. NR has been previ-
ously shown to induce mitochondrial biogenesis in BAT of normal
mice (Canto et al, 2012). NR effectively cured both the response to
cold and mitochondrial ultrastructural abnormalities in Deletors.
BAT is an active metabolic organ in mice, but recent years have
shown that BAT activity also in humans contributes to lipid metabo-
lism (Virtanen et al, 2013). Our results, indicating decreased BAT
function in MM, suggest that the tissue may contribute to mitochon-
drial disease manifestations.
UPRmt has been suggested to be beneficial for health and lifespan
(Houtkooper et al, 2010; Mouchiroud et al, 2013). We show here
that the partial pseudo-starvation response initiated by RCD in skel-
etal muscle of MM mice shares key components of UPRmt, previ-
ously characterized in detail in C. elegans (Haynes et al, 2007, 2013;
Durieux et al, 2011), and not before known to be involved in
disease. Therefore, the RCD-induced UPRmt involves mechanisms
that are conserved between worms and mammals. Importantly, NR
further enhanced UPRmt, supporting the previous finding that
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NAD+/NADH contributes to UPRmt induction (Mouchiroud et al,
2013), although it is not the sole required signal. Furthermore,
improved mitochondrial ultrastructure and function by NR, along
with enhanced UPRmt, suggests that UPRmt induction is protective
for MM.
We have previously described that fasting cytokine FGF21 is a
potential biomarker for mitochondrial myopathies (Suomalainen
et al, 2011), driven by an upstream regulatory AARE element
(Tyynismaa et al, 2010). Here, we link FGF21 (Kharitonenkov et al,
2005) to be part of UPRmt. NR further induced UPRmt and FGF21,
while COX-negative fiber amount decreased. Therefore, we propose
that FGF21 is a serum biomarker of skeletal muscle UPRmt, and part
of the pseudo-starvation response induced by RCD, which signals
and conveys the local mitochondrial activity and metabolic situation
of muscle to the whole organism. FGF21 is a valuable marker for
diagnostic use of disorders associated with UPRmt. However, upon
interventions with NAD+ precursors, or treatment trials enhancing
UPRmt, also FGF21 would be induced, and in those situations,
FGF21 serum concentrations may not reflect muscle treatment
response.
A B C D
E F G H
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Our data suggest that conflicting nutrient signaling is integral for
MM pathogenesis and disease progression. We show that fine tuning
of cellular signaling with vitamin cofactors, especially NAD+ precur-
sors, is an intriguing and straightforward therapeutic strategy that
should be explored in patients with late-onset mitochondrial myopa-
thy, the most common type of adult-onset mitochondrial disorders.
Materials and Methods
Animals and study plan
All animal procedures were performed in accordance with the
guidelines by ethical board of State Provincial Office for Animal
Figure 3. Decreased brown adipose tissue (BAT) function in Deletors and the effects of nicotinamide riboside treatment for whole-bodymetabolism, BAT, and
liver.
A, B Oxygen consumption of post-manifestation NR- and CD-treated Deletor and WT mice. CLAMS® metabolic cage analysis, the final 24-h recording from a total of 72 h.
“Light” indicates the hours of lights on, mice inactive. “Dark” indicates the dark hours, mice active. “Cold” indicates cold exposure at 4°C for 6 h. The P-values are
from left to right: ** = 0.0092, *** = 0.001, ** = 0.0095.
C, D Carbon dioxide production, as in A–B. **P = 0.013.
E–H Lipid content of BAT in post-manifestation NR- or CD-fed Deletors and WT mice. Oil Red O lipid staining on frozen sections with hematoxylin–eosin counterstaining.
Red indicates lipid pools in BAT. (E) Deletors on CD, (F) Deletors on NR, (G) WT on CD, (H) WT mice on NR diet.
I–L BAT ultrastructure in NR- or CD-fed Deletors and WT mice. Electron micrographs of Deletor (I, on CD; J on NR) or WT (K on CD, L on NR).
M BAT, quantification of mitochondrial crista density, as in Fig 2I.
N BAT, mtDNA copy number, post-manifestation NR- or CD-fed Deletors and WT mice. Analysis by quantitative PCR. (post, n = 12 Deletor NR, n = 11 Deletor CD, n = 8
WT NR, n = 7 WT CD).
O Liver, mtDNA copy number, post-manifestation study groups (n = 12 Deletor NR, n = 11 Deletor CD, n = 8 WT NR, n = 7 WT CD).
P–S Liver ultrastructure in NR- or CD-fed post-manifestation mice. Deletors (P, on CD; Q on NR) and WT mice (R on CD, S on NR). Arrows indicate ribosomes,
accumulating in NR-fed mice to close contact with mitochondria. Representative electron micrographs.
Data information: The bars indicate magnification; data shown in A–D (two-way ANOVA); all values are presented as mean  s.e.m. (Student’s t-test).
◂
A B C D
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Figure 4. Skeletal muscle of Deletor mice have enhanced mitochondrial unfolded protein response (UPRmt), expression of fatty acid oxidation enzymes, and
deacetylation of FOXO1, a downstream target of Sirt1.
A Skeletal muscle, total FOXO1 (total-F), and acetylated FOXO1 (ac-F) protein levels. Western blot analysis, Deletor and WT mice, on CD or NR (n = 4 for each group);
tubulin as a loading control.
B Quantification of acetylated FOXO1, from Western blot results (n = 4 in each group).
C Quantification of total FOXO1 (B), from Western blot results (n = 4 in each group).
D–F Muscle mRNA expression of fatty acid transport and oxidation proteins CD36, ACOX1, MCAD (post-manifestation Deletor NR n = 12; Deletor CD n = 11; WT NR n = 8;
WT CD n = 7; arbitrary units).
G Muscle UPRmt proteins HSP70, HSP60, ClpP in post-manifestation Deletors, and WT mice on NR- or CD-fed diet. Western blot analysis, beta-actin as a loading
control.
H Serum FGF21 in Deletors and WT mice on CD or NR diet, post-manifestation (Deletor NR n = 12; Deletor CD n = 11; WT NR n = 8; WT CD n = 7). ELISA analysis.
Data information: All values are presented as mean  s.e.m. (Student’s t-test).
Source data are available for this figure.
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Experimentation of Finland. The Deletor mouse model was generated
in C57BL/6 congenic background and has been previously character-
ized (Tyynismaa et al, 2005); WT mice were littermates from the same
congenic mouse strain C57BL/6. Deletor and WT male mice were
administered either CD diet (rodent diet with 11% fat, 65% carbohy-
drate, 24% protein of total calorie content, Altromin Spezialfutter
GmbH & Co. KG, Germany) or NR diet (rodent diet as CD, supple-
mented with 0.24% of NR). NR was custom-synthesized as previously
described (Yang et al, 2007) and was kindly provided by Amazentis
and Merck Research laboratories. The food pellets were manually
prepared by baking NR into the powdered food as described previously
(Canto et al, 2012), and the protocol followed this published protocol
in detail. The pellets were stored at 20°C. The mice were housed in
standard animal facility, under a 12-h dark/light cycle. They had ad
libitum access to food and water. The pre-manifestation group
consisted of nine Deletors and nine WT mice, and the post-manifesta-
tion group of 25 Deletors and 16 WT mice, receiving either NR or CD
diet. During the intervention, one mouse died without any notable
association with NR treatment (Deletor mouse receiving NR). For
NAD+ determination, we used additionally very old Deletor mice from
23 to 27 months of age, on standard diet.
During the intervention, the mice were regularly monitored for
weight, food consumption, and physical endurance. Their exercise
capability was measured twice by treadmill exercise test (Exer-6M
Treadmill, Columbus Instrument) at the start and the end of the
diet. The exercise test protocol consisted of the initial running speed
of 7 m/s, which was increased every 2 min with 2 m/s and contin-
ued until the animal was unable to run or repeatedly fell from the
belt at the stimulus site.
Analysis of whole-body metabolism
Oxygen consumption and carbon dioxide production, as well as
spontaneous moving and feeding activities, were recorded by
Oxymax Lab Animal Monitoring System (CLAMS; Columbus Instru-
ments, OH, USA). The mice were kept in individual cages inside a
CLAMS chamber for 3 days; the first day and night was a non-
recording adjustment period followed by a 24-h recording at room
temperature (+22°C) and a 6-h cold exposure (+4°C). Measurements
were performed for a total of 18 Deletor mice (n = 8 on NR and
n = 10 on CD) and six WT mice (n = 3 on NR and n = 3 on CD)
belonging to the post-manifestation group and for four Deletor mice
(n = 2 on NR and n = 2 on CD) and four WT mice (n = 2 on NR
and n = 2 on CD) from the pre-manifestation group. The results of
O2 consumption and CO2 production were used to calculate respira-
tory exchange rate and analyzed separately from the light (inactive)
and dark (active) periods of the day and from the cold exposure.
Morphologic analysis
Tissue sections were prepared from QF, liver, and BAT. Samples
were embedded with OCT Compound Embedding Medium (Tissue-
Tek) and snap-frozen in 2-methylbutane in liquid nitrogen. Frozen
sections (12 lm) from QF were assayed for in situ histochemical
COX and succinate dehydrogenase (SDH) activities simultaneously.
From QF sections, COX-negative and COX-negative plus SDH-
positive and normal fibers were calculated. Approximately 2000
fibers were counted from each mouse sample. The intensity of COX
histochemical activity from QF for both oxidative and non-oxidative
fibers was measured with Image J software. Frozen sections (8 lm)
from liver and BAT were stained with Oil Red O as previously
described (Ahola-Erkkila et al, 2010).
For plastic embedding, QF, liver, and BAT samples were fixed in
2.5% glutaraldehyde, treated with 1% osmium tetroxide, dehy-
drated in ethanol, and embedded in epoxy resin. Semi-thin (1 lm)
sections were stained with methyl blue (0.5% w/v) and boric acid
(1% w/v). The interesting areas for the ultrastructural analyses
were selected by the inspection of light microscopic sections. For
transmission electron microscopy, ultrathin (60–90 nm) sections
were cut on grids and stained with uranyl acetate and lead citrate
and viewed with JEOL 1400 Transmission Electron Microscope.
Crista content in both BAT and muscle was calculated as described
previously(St-Pierre et al, 2003; Canto et al, 2012) from electron
micrographs, utilizing a 1-lm “intramitochondrial measuring stick,”
placed perpendicular to cristae.
CS activity
Skeletal muscle samples were analyzed for citrate synthase activity
as described previously (Trounce et al, 1996).
DNA analyses
Total DNA was isolated from snap-frozen QF by standard proteinase
K digestion, phenol–chloroform extraction, and ethanol precipita-
tion methods. mtDNA deletion load was determined for each
Deletor mouse by semi-quantitative PCR amplification method, as
described previously (Ahola-Erkkila et al, 2010). mtDNA copy
number was analyzed for each mouse by real-time quantitative PCR
as described previously (Yatsuga & Suomalainen, 2011), utilizing
12S rRNA gene primers for mtDNA and beta-actin as a control for
nuclear two-copy gene.
Blood analyses
Blood samples were collected with cardiac puncture after mice were
sacrificed using carbon monoxide gas. Measurement of alanine
transaminase (ALAT) was performed at the Laboratory of the
Department of Equine and Small Animal Medicine, the Faculty of
Veterinary Medicine, University of Helsinki. From approximately
half of the blood volume, plasma was separated by centrifugation of
blood at 3,000 g for 5 min at +4°C, transferred to 1.5-ml tubes, and
maintained at 80°C until analysis. From serum, FGF21 (Quantiki-
new Mouse FGF-21, R&D Systems) was quantified by ELISA assay.
Microplates were read by Spectra-Max 190 Absorbance Microplate
Reader (Molecular Devices, Inc., USA) and analyzed by SoftMax Pro
(Molecular Devices, Inc.).
Gene expression analyses
Total cellular RNA from frozen muscle tissue and liver samples were
extracted in TRIzol reagent (Invitrogen) and homogenized with Fast-
Prep w-24 Lysing Matrix D (MP Biomedical) and Precellys w-24 (Ber-
tin Technologies) for 15 s. Two micrograms of total RNA was used
to generate cDNA using Maxima first-strand cDNA synthesis kit
(K1641; Thermo Scientific). Specificity of amplification was tested by
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PCR and agarose gel electrophoresis. Quantitative real-time PCR
amplification of cDNA generated from mouse tissues was performed
with DyNAmo Flash SYBR Green qPCR kit (Finnzymes) on CFX96
Touch qPCR system (Bio-Rad) and quantified on exponential phase
of PCR. Primer sets are available from authors on request.
NAD+ determination
HPLC analysis: For NAD+ extraction, 500 ll of 1.66 M HClO4 was
added to the 4–10 mg pieces of frozen tissues and homogenized in
CKMix tubes (Precellys), thrice, for 20 s each, at 4,000 rpm of homoge-
nizing speed in Precellys homogenizer with 2-min breaks on ice.
Tissue homogenates were centrifuged at 20,000 g for 10 min, +4°C.
117 ll of 3M K2CO3 was added to 350 ll of supernatants, exothermic
reaction stopped, and the samples were vortexed and centrifuged at
14,000 rpm for 5 min at +4°C. Supernatants containing NAD+ were
frozen at 80°C. NAD+ extracts were thawed and centrifuged at
14,000 rpm for 5 min at +4°C and quantified on HPLC column Poro-
shell 120 EC-C18, with dimensions 3.0 × 50 mm and particle size
2.7 lm (Agilent) using A¨ktaPurifier UPC10 system (GE Healthcare).
The column was equilibrated with 9.6 mM KH2PO4, 154 mM K2HPO4,
pH 7.02. Flow rate was 0.6 ml/min, and detection was at 254 nm. Fifty
microliters of the NAD+ extract was injected into the column and
eluted isocratically with the same mobile phase. Retention volume for
NAD+ varied between 0.68 and 0.74 ml. NAD+ content in the extracts
was calculated based on the NAD+ standard curve for concentrations
from 0.5 to 10 lM and normalized on mass of tissue.
Mass spectrometry analysis: Polar metabolites were extracted
from mouse muscle samples, separated using Waters Acquity ultra
performance liquid chromatography, and analyzed using triple
quadrupole mass spectrometry. For method details, see Supplemen-
tary information.
Western Blotting
Whole-tissue lysates were prepared from a piece of QF homogenized
in ice-cold PBS using a Precellys homogenizer and lysed in RIPA
buffer with protein inhibitor (Complete Mini, Roche), followed by
incubation on ice for 20 min. Protein concentration was measured
using the Bradford method (Protein Assay, Bio-Rad). Ten micro-
grams of protein was loaded per well in SDS–PAGE and transferred
to Immobilon-FL transfer membrane (Millipore) using semi-dry
transfer unit (Hoefer TE70, Amersham Biosciences). The
membranes were blocked in 5% milk in TBS 0.1% Tween. Antibody
detection reaction was developed by enhanced chemiluminescence
(Bio-Rad). The anti-FOXO1 antibody was from Cell Signaling, and
the beta-tubulin antibody was from Sigma; HSP70 and mitochon-
drial respiratory complex antibodies were from Abcam, against CI,
respiratory chain complex I, 39-kDa subunit; CII, complex II, 70-kDa
subunit; CIV, complex IV, cytochrome c oxidase, COI subunit, 40
kDa; CV, complex V, ATPase, alpha subunit, 55 kDa, ClpP antibody
from Proteintech, and antibodies for HSP60, acetylated-FOXO1
(sc-43497), and beta-actin were from Santa-Cruz.
Statistics
All results in the figures are expressed as mean  s.e.m., unless
otherwise specified. One-way ANOVA was used for mice and food
weight, blood and serum tests, and CLAMS data. Other studies were
evaluated using unpaired Student’s t-test. Statistical analyses were
performed with PRISM 6.0 (GraphPad software).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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The paper explained
Problem
Mitochondrial disorders are the most common cause of inherited
metabolic disease of adults and children, with no means of cure.
Physiological studies utilizing mouse models have suggested that
energy metabolic defect in adult muscle is interpreted by some cellu-
lar pathways as a state of starvation, despite normal nutrition, leading
to “pseudo-starvation” response. One of the cellular mediators for this
response is the ratio of oxidized (NAD+) to reduced (NADH) nicotin-
amide adenine dinucleotide. Vitamin B3 is a direct precursor of NAD+.
We asked here whether increasing cellular NAD+ levels by a vitamin
B3 form, nicotinamide riboside (NR), could alleviate pathological
changes upon mitochondrial myopathy (MM) or delay disease
progression.
Results
We report that per-oral NR, a vitamin B3 form and NAD+ precursor,
effectively delayed mouse MM progression. NR robustly induced mito-
chondrial mass and function and cured structural abnormalities of
mitochondria, as well as delayed accumulation of mitochondrial DNA
mutations. We show here that MM pseudo-starvation response is
linked with a protective stress response, mitochondrial unfolded
protein response (UPRmt), with induction of fasting cytokine FGF21.
NR further enhanced UPRmt, supporting a protective role of UPRmt
upon MM.
Impact
We show that the conflicting nutrient signaling is an integral part of
MM and that fine tuning of the cellular signaling with oral adminis-
tration of vitamin cofactors, such as NR, is highly beneficial and
attenuating the disease progression of disease phenotype. These
results indicate that vitamin cofactors modify metabolism and that
treatment strategies increasing NAD+ should be explored in the
patients.
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